NOUGUES MAXIMO F sold $78K of PBYI
NOUGUES MAXIMO F (Chief Financial Officer) sold 9,386 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $8.26 on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO’s open-market sale is disclosed with execution price, share count, and confirmation of a pre-arranged 10b5-1 plan, which typically reduces interpretive value.
Market read
This is a routine insider sale filing; it may cause minor sentiment noise but does not introduce new fundamental information.
What to watch
Traders may over-weight insider sales; without accompanying operational or guidance changes, the signal is usually weak.
Background
The article is an SEC Form 4 insider transaction disclosure for PUMA Biotechnology, Inc. (PBYI).
Ticker impact
PBYI CFO sold 9,386 shares in an open-market transaction at $8.2630 on 2026-07-06 under a 10b5-1 plan.
Likely minimal near-term impact; any reaction should be small and short-lived unless accompanied by other news.
Form 4 details an insider’s planned sale size and price, but provides no new company performance, guidance, or regulatory development.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still reflect risk management or liquidity needs rather than bearish fundamentals.
Key entities
- issuerPUMA BIOTECHNOLOGY, INC.
Subject of the Form 4 insider transaction disclosure.
- insiderNOUGUES MAXIMO F
Chief Financial Officer who executed the sale under a 10b5-1 plan.
